170 related articles for article (PubMed ID: 36323745)
21. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.
Hinterberger M; Reineke T; Storz M; Weder W; Vogt P; Moch H
Mod Pathol; 2007 Feb; 20(2):248-55. PubMed ID: 17361207
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
Ordóñez NG
Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
[TBL] [Abstract][Full Text] [Related]
23. Calretinin as a blood-based biomarker for mesothelioma.
Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
[TBL] [Abstract][Full Text] [Related]
24. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
Naso JR; Churg A
Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
[TBL] [Abstract][Full Text] [Related]
25. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms.
Attanoos RL; Dojcinov SD; Webb R; Gibbs AR
Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698
[TBL] [Abstract][Full Text] [Related]
26. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
[TBL] [Abstract][Full Text] [Related]
27. Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma.
Kuraoka M; Amatya VJ; Kushitani K; Mawas AS; Miyata Y; Okada M; Kishimoto T; Inai K; Nishisaka T; Sueda T; Takeshima Y
Am J Surg Pathol; 2017 Aug; 41(8):1045-1052. PubMed ID: 28394802
[TBL] [Abstract][Full Text] [Related]
28. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2001 Dec; 39(6):584-8. PubMed ID: 11903576
[TBL] [Abstract][Full Text] [Related]
29. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
30. Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.
Kai Y; Amatya VJ; Kushitani K; Kambara T; Suzuki R; Tsutani Y; Miyata Y; Okada M; Takeshima Y
Histopathology; 2019 Mar; 74(4):545-554. PubMed ID: 30329165
[TBL] [Abstract][Full Text] [Related]
31. Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.
Chiu K; Lee L; Cheung S; Churg AM
Mod Pathol; 2018 Sep; 31(9):1400-1403. PubMed ID: 29785020
[TBL] [Abstract][Full Text] [Related]
32. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
Miettinen M; Sarlomo-Rikala M
Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
[TBL] [Abstract][Full Text] [Related]
33. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
34. [Value of immunocytochemistry in differential diagnosis of gastric adenocarcinoma, reactive mesothelial cells and malignant epithelial mesothelioma in metastatic effusion fluid].
Lyu M; Cha N; Zou YF; Leng JH; Xu L; Sun Y; Hao YY
Zhonghua Bing Li Xue Za Zhi; 2018 Mar; 47(3):180-185. PubMed ID: 29534357
[No Abstract] [Full Text] [Related]
35. Epithelioid angiosarcoma at chest wall which needs to be carefully distinguished from malignant mesothelioma: report of a rare case.
Fan C; Liu Y; Lin X; Han Y; He A; Wang E
Int J Clin Exp Pathol; 2014; 7(12):9056-60. PubMed ID: 25674287
[TBL] [Abstract][Full Text] [Related]
36. Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
Chaouche-Mazouni S; Scherpereel A; Zaamoum R; Mihalache A; Amir ZC; Lebaïli N; Delaire B; Gosset P
Ann Diagn Pathol; 2015 Aug; 19(4):193-7. PubMed ID: 25935651
[TBL] [Abstract][Full Text] [Related]
37. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
Amatya VJ; Takeshima Y; Kohno H; Kushitani K; Yamada T; Morimoto C; Inai K
Histopathology; 2009 Jul; 55(1):10-9. PubMed ID: 19614762
[TBL] [Abstract][Full Text] [Related]
38. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
[TBL] [Abstract][Full Text] [Related]
39. Malignant mesothelioma: A histomorphological and immunohistochemical study of 24 cases from a tertiary care hospital in Southern India.
Hui M; Uppin SG; Bhaskar K; Kumar NN; Paramjyothi GK
Indian J Cancer; 2018; 55(2):190-195. PubMed ID: 30604735
[TBL] [Abstract][Full Text] [Related]
40. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
